An Open Label, Phase I Dose-finding Study of BI 754111 in Combination With BI 754091 in Patients With Advanced Solid Cancers Followed by Expansion Cohorts at the Selected Dose of the Combination in Patients With Non-small Cell Lung Cancer and Other Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2018
At a glance
- Drugs BI 754091 (Primary) ; BI 754111 (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 02 Aug 2018 Planned End Date changed from 15 Nov 2019 to 1 Aug 2020.
- 02 Aug 2018 Planned primary completion date changed from 15 Nov 2019 to 1 Aug 2020.
- 05 Feb 2018 Planned number of patients changed from 75 to 70.